Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study.

Price DB, Voorham J, Brusselle G, Clemens A, Kostikas K, Stephens JW, Park HY, Roche N, Fogel R.

NPJ Prim Care Respir Med. 2019 Oct 28;29(1):38. doi: 10.1038/s41533-019-0150-x.

2.

Management Of Community-Acquired Pneumonia: An Observational Study In UK Primary Care.

Launders N, Ryan D, Winchester CC, Skinner D, Konduru PR, Price DB.

Pragmat Obs Res. 2019 Sep 23;10:53-65. doi: 10.2147/POR.S211198. eCollection 2019.

3.

Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management.

Bleecker ER, Menzies-Gow AN, Price DB, Bourdin A, Sweet S, Martin AL, Alacqua M, Tran TN.

Am J Respir Crit Care Med. 2019 Sep 16. doi: 10.1164/rccm.201904-0903SO. [Epub ahead of print]

PMID:
31525297
4.

Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations.

Price DB, Bosnic-Anticevich S, Pavord ID, Roche N, Halpin DMG, Bjermer L, Usmani OS, Brusselle G, Ming SWY, Rastogi S.

Clin Transl Allergy. 2019 Aug 21;9:41. doi: 10.1186/s13601-019-0282-7. eCollection 2019.

5.

Understanding reliever overuse in patients purchasing over-the-counter short-acting beta2 agonists: an Australian community pharmacy-based survey.

Azzi EA, Kritikos V, Peters MJ, Price DB, Srour P, Cvetkovski B, Bosnic-Anticevich S.

BMJ Open. 2019 Aug 14;9(8):e028995. doi: 10.1136/bmjopen-2019-028995.

6.

A Patient-Centered Description of Severe Asthma: Patient Understanding Leading to Assessment for a Severe Asthma Referral (PULSAR).

Winders TA, Wilson AM, Fletcher MJ, McGuinness A, Price DB.

Patient. 2019 Oct;12(5):539-549. doi: 10.1007/s40271-019-00371-0.

7.

Real-life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred-dose inhalers in patients with asthma treated with ICS/LABA.

Park HS, Yoon D, Lee HY, Ban GY, Wan Yau Ming S, Jie JLZ, Carter V, Hardjojo A, Van Boven JFM, Price DB.

Respirology. 2019 Oct;24(10):972-979. doi: 10.1111/resp.13559. Epub 2019 Apr 30.

PMID:
31038269
8.

Matched cohort study of therapeutic strategies to prevent preschool wheezing/asthma attacks.

Grigg J, Nibber A, Paton JY, Chisholm A, Guilbert TW, Kaplan A, Turner S, Roche N, Hillyer EV, Price DB; Respiratory Effectiveness Group.

J Asthma Allergy. 2018 Dec 11;11:309-321. doi: 10.2147/JAA.S178531. eCollection 2018.

9.

Physiological predictors Of peak inspiRatory flow using Observed lung function resultS (POROS): evaluation at discharge among patients hospitalized for a COPD exacerbation.

Price DB, Yang S, Ming SWY, Hardjojo A, Cabrera C, Papaioannou AI, Loukides S, Kritikos V, Bosnic-Anticevich SZ, Carter V, Dorinsky PM.

Int J Chron Obstruct Pulmon Dis. 2018 Dec 13;13:3937-3946. doi: 10.2147/COPD.S174371. eCollection 2018.

10.

Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK.

Voorham J, Roche N, Benhaddi H, van der Tol M, Carter V, van Boven JFM, Bjermer L, Miravitlles M, Price DB.

BMJ Open. 2018 Oct 27;8(10):e022051. doi: 10.1136/bmjopen-2018-022051. Erratum in: BMJ Open. 2018 Dec 9;8(12):e022051corr1. BMJ Open. 2019 Jun 14;9(6):e022051corr2.

11.

Pediatric asthma: An unmet need for more effective, focused treatments.

Papadopoulos NG, Čustović A, Cabana MD, Dell SD, Deschildre A, Hedlin G, Hossny E, Le Souëf P, Matricardi PM, Nieto A, Phipatanakul W, Pitrez PM, Pohunek P, Gavornikova M, Jaumont X, Price DB.

Pediatr Allergy Immunol. 2019 Feb;30(1):7-16. doi: 10.1111/pai.12990. Epub 2018 Nov 15. Review.

12.

Does Changing Inhaler Device Impact Real-Life Asthma Outcomes? Clinical and Economic Evaluation.

Rhee CK, van Boven JFM, Yau Ming SW, Park HY, Kim DK, Park HS, Ling JZJ, Yoo KH, Price DB.

J Allergy Clin Immunol Pract. 2019 Mar;7(3):934-942. doi: 10.1016/j.jaip.2018.09.027. Epub 2018 Oct 5.

PMID:
30292924
13.

Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study.

Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, Tran TN.

J Asthma Allergy. 2018 Aug 29;11:193-204. doi: 10.2147/JAA.S176026. eCollection 2018.

14.

Real-life treatment of rhinitis in Australia: a historical cohort study of prescription and over-the-counter therapies for patients with and without additional respiratory disease.

Price DB, Smith PK, Harvey RJ, Carney AS, Kritikos V, Bosnic-Anticevich SZ, Christian L, Skinner D, Carter V, Durieux AM.

Pragmat Obs Res. 2018 Aug 15;9:43-54. doi: 10.2147/POR.S153266. eCollection 2018.

15.

Performance of database-derived severe exacerbations and asthma control measures in asthma: responsiveness and predictive utility in a UK primary care database with linked questionnaire data.

Colice G, Chisholm A, Dima AL, Reddel HK, Burden A, Martin RJ, Brusselle G, Popov TA, von Ziegenweidt J, Price DB.

Pragmat Obs Res. 2018 Aug 10;9:29-42. doi: 10.2147/POR.S151615. eCollection 2018.

16.

Association between blood eosinophil count and risk of readmission for patients with asthma: Historical cohort study.

Kerkhof M, Tran TN, van den Berge M, Brusselle GG, Gopalan G, Jones RCM, Kocks JWH, Menzies-Gow A, Nuevo J, Pavord ID, Rastogi S, Price DB.

PLoS One. 2018 Jul 25;13(7):e0201143. doi: 10.1371/journal.pone.0201143. eCollection 2018.

17.

Applying UK real-world primary care data to predict asthma attacks in 3776 well-characterised children: a retrospective cohort study.

Turner SW, Murray C, Thomas M, Burden A, Price DB.

NPJ Prim Care Respir Med. 2018 Jul 23;28(1):28. doi: 10.1038/s41533-018-0095-5.

18.

Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma.

Voorham J, Xu X, Price DB, Golam S, Davis J, Zhi Jie Ling J, Kerkhof M, Ow M, Tran TN.

Allergy. 2019 Feb;74(2):273-283. doi: 10.1111/all.13556. Epub 2018 Nov 20.

19.

Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study.

Price DB, Thomas V, Richard Dekhuijzen PN, Bosnic-Anticevich S, Roche N, Lavorini F, Raju P, Freeman D, Nicholls C, Small IR, Sims E, Safioti G, Canvin J, Chrystyn H.

BMC Pulm Med. 2018 Jun 28;18(1):107. doi: 10.1186/s12890-018-0665-x.

20.

Exogenous sex steroid hormones and asthma in females: protocol for a population-based retrospective cohort study using a UK primary care database.

Nwaru BI, Simpson CR, Soyiri IN, Pillinger R, Appiagyei F, Ryan D, Critchley H, Price DB, Hawrylowicz CM, Sheikh A.

BMJ Open. 2018 Jun 27;8(6):e020075. doi: 10.1136/bmjopen-2017-020075.

21.

Relationship of Inhaled Corticosteroid Adherence to Asthma Exacerbations in Patients with Moderate-to-Severe Asthma.

Papi A, Ryan D, Soriano JB, Chrystyn H, Bjermer L, Rodríguez-Roisin R, Dolovich MB, Harris M, Wood L, Batsiou M, Thornhill SI, Price DB.

J Allergy Clin Immunol Pract. 2018 Nov - Dec;6(6):1989-1998.e3. doi: 10.1016/j.jaip.2018.03.008. Epub 2018 Apr 5.

PMID:
29627457
22.

Evaluation of criteria for clinical control in a prospective, international, multicenter study of patients with COPD.

Miravitlles M, Sliwinski P, Rhee CK, Costello RW, Carter V, Tan J, Lapperre TS, Alcazar B, Gouder C, Esquinas C, García-Rivero JL, Kemppinen A, Tee A, Roman-Rodríguez M, Soler-Cataluña JJ, Price DB.

Respir Med. 2018 Mar;136:8-14. doi: 10.1016/j.rmed.2018.01.019. Epub 2018 Jan 31.

PMID:
29501251
23.

Real-life effectiveness and safety of salbutamol Steri-Neb™ vs. Ventolin Nebules® for exacerbations in patients with COPD: Historical cohort study.

Price DB, Gefen E, Gopalan G, McDonald R, Thomas V, Ming SWY, Davis E.

PLoS One. 2018 Jan 24;13(1):e0191404. doi: 10.1371/journal.pone.0191404. eCollection 2018.

24.

The effect of smoking on exacerbation risk in eosinophilic patients with COPD.

Kerkhof M, Hillyer EV, Price DB; all authors.

Eur Respir J. 2017 Dec 21;50(6). pii: 1702086. doi: 10.1183/13993003.02086-2017. Print 2017 Dec. No abstract available.

25.

Harmonizing the Nomenclature for Therapeutic Aerosol Particle Size: A Proposal.

Hillyer EV, Price DB, Chrystyn H, Martin RJ, Israel E, van Aalderen WMC, Papi A, Usmani OS, Roche N.

J Aerosol Med Pulm Drug Deliv. 2018 Apr;31(2):111-113. doi: 10.1089/jamp.2017.1396. Epub 2017 Nov 28. No abstract available.

26.

Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial.

Price DB, Buhl R, Chan A, Freeman D, Gardener E, Godley C, Gruffydd-Jones K, McGarvey L, Ohta K, Ryan D, Syk J, Tan NC, Tan T, Thomas M, Yang S, Konduru PR, Ngantcha M, d'Alcontres MS, Lapperre TS.

Lancet Respir Med. 2018 Jan;6(1):29-39. doi: 10.1016/S2213-2600(17)30424-1. Epub 2017 Nov 3.

PMID:
29108938
27.

Myelography: From Lipid-Based to Gadolinium-Based Contrast Agents.

Price DB, Ortiz AO.

Magn Reson Imaging Clin N Am. 2017 Nov;25(4):713-724. doi: 10.1016/j.mric.2017.06.005. Epub 2017 Aug 23. Review.

PMID:
28964461
28.

Extrafine Versus Fine Inhaled Corticosteroids in Relation to Asthma Control: A Systematic Review and Meta-Analysis of Observational Real-Life Studies.

Sonnappa S, McQueen B, Postma DS, Martin RJ, Roche N, Grigg J, Guilbert T, Gouder C, Pizzichini E, Niimi A, Phipatanakul W, Chisholm A, Dandurand RJ, Kaplan A, Israel E, Papi A, van Aalderen WMC, Usmani OS, Price DB.

J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):907-915.e7. doi: 10.1016/j.jaip.2017.07.032. Epub 2017 Sep 20.

29.

Seasonal patterns of oral antihistamine and intranasal corticosteroid purchases from Australian community pharmacies: a retrospective observational study.

Carney AS, Price DB, Smith PK, Harvey R, Kritikos V, Bosnic-Anticevich SZ, Christian L, Skinner DA, Carter V, Durieux AM.

Pragmat Obs Res. 2017 Aug 30;8:157-165. doi: 10.2147/POR.S134266. eCollection 2017.

30.

Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population.

Kerkhof M, Tran TN, Soriano JB, Golam S, Gibson D, Hillyer EV, Price DB.

Thorax. 2018 Feb;73(2):116-124. doi: 10.1136/thoraxjnl-2017-210531. Epub 2017 Sep 16.

31.

Initiating or changing to a fixed-dose combination of Fluticasone propionate/Formoterol over Fluticasone propionate/Salmeterol: A real-life effectiveness and cost impact evaluation.

Wan Yau Ming S, Haughney J, Small I, Wolfe S, Hamill J, Gruffydd-Jones K, Daly C, Soriano JB, Gardener E, Skinner D, Stagno d'Alcontres M, Price DB.

Respir Med. 2017 Aug;129:199-206. doi: 10.1016/j.rmed.2017.06.016. Epub 2017 Jun 24.

32.

Blood eosinophil count and exacerbation risk in patients with COPD.

Kerkhof M, Sonnappa S, Postma DS, Brusselle G, Agustí A, Anzueto A, Jones R, Papi A, Pavord I, Pizzichini E, Popov T, Roche N, Ryan D, Thomas M, Vogelmeier C, Chisholm A, Freeman D, Bafadhel M, Hillyer EV, Price DB.

Eur Respir J. 2017 Jul 20;50(1). pii: 1700761. doi: 10.1183/13993003.00761-2017. Print 2017 Jul. No abstract available.

33.

Reply.

Guilbert TW, Price DB.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1163-1164. doi: 10.1016/j.jaip.2017.03.010. No abstract available.

PMID:
28689834
34.

Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids.

Sonnappa S, Martin R, Israel E, Postma D, van Aalderen W, Burden A, Usmani OS, Price DB; Respiratory Effectiveness Group, Small Airways Study Group.

PLoS One. 2017 Jun 15;12(6):e0178112. doi: 10.1371/journal.pone.0178112. eCollection 2017.

35.

Real-life effectiveness and safety of the inhalation suspension budesonide comparator vs the originator product for the treatment of patients with asthma: a historical cohort study using a US health claims database.

Price DB, Gefen E, Gopalan G, Miglio C, McDonald R, Thomas V, Wan Yau Ming S.

Pragmat Obs Res. 2017 May 18;8:69-83. doi: 10.2147/POR.S132839. eCollection 2017.

36.

Urging Europe to put non-adherence to inhaled respiratory medication higher on the policy agenda: a report from the First European Congress on Adherence to Therapy.

van Boven JFM, Lavorini F, Dekhuijzen PNR, Blasi F, Price DB, Viegi G.

Eur Respir J. 2017 May 19;49(5). pii: 1700076. doi: 10.1183/13993003.00076-2017. Print 2017 May. No abstract available.

37.

Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study.

Dollerup J, Vestbo J, Murray-Thomas T, Kaplan A, Martin RJ, Pizzichini E, Pizzichini MMM, Burden A, Martin J, Price DB.

Clin Epidemiol. 2017 Apr 26;9:231-243. doi: 10.2147/CLEP.S127775. eCollection 2017.

38.

Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical, matched cohort study.

Voorham J, Vrijens B, van Boven JF, Ryan D, Miravitlles M, Law LM, Price DB.

Pragmat Obs Res. 2017 Apr 18;8:31-41. doi: 10.2147/POR.S132658. eCollection 2017.

39.

An evaluation of exact matching and propensity score methods as applied in a comparative effectiveness study of inhaled corticosteroids in asthma.

Burden A, Roche N, Miglio C, Hillyer EV, Postma DS, Herings RM, Overbeek JA, Khalid JM, van Eickels D, Price DB.

Pragmat Obs Res. 2017 Mar 22;8:15-30. doi: 10.2147/POR.S122563. eCollection 2017.

40.

Comparative Effectiveness of Step-up Therapies in Children with Asthma Prescribed Inhaled Corticosteroids: A Historical Cohort Study.

Murray CS, Thomas M, Richardson K, Price DB, Turner SW.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1082-1090.e7. doi: 10.1016/j.jaip.2016.12.028. Epub 2017 Mar 27.

PMID:
28351789
41.

Personalising care of adults with asthma from Asia: a modified e-Delphi consensus study to inform management tailored to attitude and control profiles.

Chisholm A, Price DB, Pinnock H, Tan TL, Roa C, Cho SH, David-Wang A, Wong G, van der Molen T, Ryan D, Castillo-Carandang N, Yong YV.

NPJ Prim Care Respir Med. 2017 Mar 23;27:17002. doi: 10.1038/npjpcrm.2017.2. No abstract available.

42.

Inhaler technique mastery and maintenance in healthcare professionals trained on different devices.

Bosnic-Anticevich S, Callan C, Chrystyn H, Lavorini F, Nikolaou V, Kritikos V, Dekhuijzen PNR, Roche N, Bjermer L, Rand C, Zwar N, Price DB.

J Asthma. 2018 Jan;55(1):79-88. doi: 10.1080/02770903.2017.1310227. Epub 2017 Apr 28.

PMID:
28332886
43.

Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes.

Price DB, Román-Rodríguez M, McQueen RB, Bosnic-Anticevich S, Carter V, Gruffydd-Jones K, Haughney J, Henrichsen S, Hutton C, Infantino A, Lavorini F, Law LM, Lisspers K, Papi A, Ryan D, Ställberg B, van der Molen T, Chrystyn H.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1071-1081.e9. doi: 10.1016/j.jaip.2017.01.004. Epub 2017 Mar 9.

PMID:
28286157
44.

Urinary prostanoids in preschool wheeze.

Grigg J, Whitehouse A, Pandya H, Turner S, Griffiths CJ, Vulliamy T, T Walton R, Price DB, Sanak M, Holloway JW, Noimark L, Lesosky M, Brugha R, Koh L, Nwokoro C.

Eur Respir J. 2017 Feb 2;49(2). pii: 1601390. doi: 10.1183/13993003.01390-2016. Print 2017 Feb. No abstract available.

45.

Real-Life Outcomes for Patients with Asthma Prescribed Spacers for Use with Either Extrafine- or Fine-Particle Inhaled Corticosteroids.

Guilbert TW, Colice G, Grigg J, van Aalderen W, Martin RJ, Israel E, Postma DS, Roche N, Phipatanakul W, Hillyer EV, Evans JM, Dolovich MB, Price DB; Respiratory Effectiveness Group.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1040-1049.e4. doi: 10.1016/j.jaip.2016.11.026. Epub 2017 Jan 18.

PMID:
28110057
46.

Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids.

Postma DS, Dekhuijzen R, van der Molen T, Martin RJ, van Aalderen W, Roche N, Guilbert TW, Israel E, van Eickels D, Khalid JM, Herings RM, Overbeek JA, Miglio C, Thomas V, Hutton C, Hillyer EV, Price DB.

Allergy Asthma Immunol Res. 2017 Mar;9(2):116-125. doi: 10.4168/aair.2017.9.2.116.

47.

Personalising care of adults with asthma from Asia: a modified e-Dephi consensus study to inform management tailored to attitude and control profiles.

Chisholm A, Price DB, Pinnock H, Lee TT, Roa C, Cho SH, David-Wang A, Wong G, van der Molen T, Ryan D, Castillo-Carandang N, Yong YV.

NPJ Prim Care Respir Med. 2017 Jan 5;27:16089. doi: 10.1038/npjpcrm.2016.89. Erratum in: NPJ Prim Care Respir Med. 2017 Mar 23;27:17002.

48.

The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes.

Bosnic-Anticevich S, Chrystyn H, Costello RW, Dolovich MB, Fletcher MJ, Lavorini F, Rodríguez-Roisin R, Ryan D, Wan Yau Ming S, Price DB.

Int J Chron Obstruct Pulmon Dis. 2016 Dec 21;12:59-71. doi: 10.2147/COPD.S117196. eCollection 2017. Erratum in: Int J Chron Obstruct Pulmon Dis. 2019 Aug 02;14:1739.

49.

Identifying Risk of Future Asthma Attacks Using UK Medical Record Data: A Respiratory Effectiveness Group Initiative.

Blakey JD, Price DB, Pizzichini E, Popov TA, Dimitrov BD, Postma DS, Josephs LK, Kaplan A, Papi A, Kerkhof M, Hillyer EV, Chisholm A, Thomas M.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1015-1024.e8. doi: 10.1016/j.jaip.2016.11.007. Epub 2016 Dec 22.

PMID:
28017629
50.

It is important to distinguish between HFrEF and HFpEF when interpreting these data.

Lipworth B, Skinner D, Devereux G, Thomas V, Ling Zhi Jie J, Martin J, Carter V, Price DB.

Heart. 2016 Dec 1;102(23):1934. doi: 10.1136/heartjnl-2016-310557. No abstract available.

PMID:
27836947

Supplemental Content

Loading ...
Support Center